Australia markets close in 35 minutes
  • ALL ORDS

    7,278.60
    -46.80 (-0.64%)
     
  • ASX 200

    7,021.30
    -49.70 (-0.70%)
     
  • AUD/USD

    0.7124
    +0.0017 (+0.24%)
     
  • OIL

    93.80
    -0.54 (-0.57%)
     
  • GOLD

    1,806.90
    -0.30 (-0.02%)
     
  • BTC-AUD

    33,685.43
    -1,056.52 (-3.04%)
     
  • CMC Crypto 200

    570.56
    -4.18 (-0.73%)
     
  • AUD/EUR

    0.6898
    +0.0019 (+0.28%)
     
  • AUD/NZD

    1.1014
    -0.0033 (-0.30%)
     
  • NZX 50

    11,730.52
    -29.49 (-0.25%)
     
  • NASDAQ

    13,291.99
    -86.33 (-0.65%)
     
  • FTSE

    7,465.91
    -41.20 (-0.55%)
     
  • Dow Jones

    33,336.67
    +27.16 (+0.08%)
     
  • DAX

    13,694.51
    -6.42 (-0.05%)
     
  • Hang Seng

    20,156.91
    +74.48 (+0.37%)
     
  • NIKKEI 225

    28,494.62
    +675.29 (+2.43%)
     

Concord Medical Services Holdings (NYSE:CCM) adds CN¥10.0m to market cap in the past 7 days, though investors from five years ago are still down 62%

  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

This week we saw the Concord Medical Services Holdings Limited (NYSE:CCM) share price climb by 17%. But that is little comfort to those holding over the last half decade, sitting on a big loss. Indeed, the share price is down 62% in the period. So we're not so sure if the recent bounce should be celebrated. However, in the best case scenario (far from fait accompli), this improved performance might be sustained.

On a more encouraging note the company has added CN¥10.0m to its market cap in just the last 7 days, so let's see if we can determine what's driven the five-year loss for shareholders.

View our latest analysis for Concord Medical Services Holdings

Concord Medical Services Holdings isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

In the last five years Concord Medical Services Holdings saw its revenue shrink by 4.4% per year. While far from catastrophic that is not good. The share price decline of 10% compound, over five years, is understandable given the company is losing money, and revenue is moving in the wrong direction. The chance of imminent investor enthusiasm for this stock seems slimmer than Louise Brooks. Not that many investors like to invest in companies that are losing money and not growing revenue.

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

earnings-and-revenue-growth
earnings-and-revenue-growth

Take a more thorough look at Concord Medical Services Holdings' financial health with this free report on its balance sheet.

A Different Perspective

While the broader market lost about 9.4% in the twelve months, Concord Medical Services Holdings shareholders did even worse, losing 51%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 10% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For example, we've discovered 4 warning signs for Concord Medical Services Holdings (2 are a bit concerning!) that you should be aware of before investing here.

Of course Concord Medical Services Holdings may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting